The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Dilated Cardiomyopathy Therapeutic Market Research Report 2025
Synopsis
Dilated cardiomyopathy (DCM) is characterized by LV (left ventricular) or biventricular systolic dysfunction and dilation, not explained by abnormal loading conditions or coronary artery disease.
The global Dilated Cardiomyopathy Therapeutic market was valued at US$ 319.4 million in 2023 and is anticipated to reach US$ 418.1 million by 2030, witnessing a CAGR of 3.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Dilated Cardiomyopathy Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dilated Cardiomyopathy Therapeutic.
Report Scope
The Dilated Cardiomyopathy Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dilated Cardiomyopathy Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dilated Cardiomyopathy Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Array BioPharma, Inc.
AstraZeneca plc.
Celladon Corporation
GlaxoSmithKline plc
Janssen Pharmaceuticals, Inc. (J&J)
Merck & Co., Inc.
Novartis International AG
Pfizer, Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Vericel Corporation
Segment by Type
Aldosterone antagonists
Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin II receptor blockers (ARBs)
Beta-blockers
Segment by Application
Hospitals
Academic Institutions
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dilated Cardiomyopathy Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Dilated cardiomyopathy (DCM) is characterized by LV (left ventricular) or biventricular systolic dysfunction and dilation, not explained by abnormal loading conditions or coronary artery disease.
The global Dilated Cardiomyopathy Therapeutic market was valued at US$ 319.4 million in 2023 and is anticipated to reach US$ 418.1 million by 2030, witnessing a CAGR of 3.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Dilated Cardiomyopathy Therapeutic, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Dilated Cardiomyopathy Therapeutic.
Report Scope
The Dilated Cardiomyopathy Therapeutic market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Dilated Cardiomyopathy Therapeutic market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Dilated Cardiomyopathy Therapeutic companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Array BioPharma, Inc.
AstraZeneca plc.
Celladon Corporation
GlaxoSmithKline plc
Janssen Pharmaceuticals, Inc. (J&J)
Merck & Co., Inc.
Novartis International AG
Pfizer, Inc.
Sanofi S.A.
Teva Pharmaceutical Industries Ltd.
Vericel Corporation
Segment by Type
Aldosterone antagonists
Angiotensin-converting enzyme (ACE) inhibitors
Angiotensin II receptor blockers (ARBs)
Beta-blockers
Segment by Application
Hospitals
Academic Institutions
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Dilated Cardiomyopathy Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Dilated Cardiomyopathy Therapeutic Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Aldosterone antagonists
1.2.3 Angiotensin-converting enzyme (ACE) inhibitors
1.2.4 Angiotensin II receptor blockers (ARBs)
1.2.5 Beta-blockers
1.3 Market by Application
1.3.1 Global Dilated Cardiomyopathy Therapeutic Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Academic Institutions
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Dilated Cardiomyopathy Therapeutic Market Perspective (2019-2030)
2.2 Dilated Cardiomyopathy Therapeutic Growth Trends by Region
2.2.1 Global Dilated Cardiomyopathy Therapeutic Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Dilated Cardiomyopathy Therapeutic Historic Market Size by Region (2019-2024)
2.2.3 Dilated Cardiomyopathy Therapeutic Forecasted Market Size by Region (2025-2030)
2.3 Dilated Cardiomyopathy Therapeutic Market Dynamics
2.3.1 Dilated Cardiomyopathy Therapeutic Industry Trends
2.3.2 Dilated Cardiomyopathy Therapeutic Market Drivers
2.3.3 Dilated Cardiomyopathy Therapeutic Market Challenges
2.3.4 Dilated Cardiomyopathy Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Dilated Cardiomyopathy Therapeutic Players by Revenue
3.1.1 Global Top Dilated Cardiomyopathy Therapeutic Players by Revenue (2019-2024)
3.1.2 Global Dilated Cardiomyopathy Therapeutic Revenue Market Share by Players (2019-2024)
3.2 Global Dilated Cardiomyopathy Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Dilated Cardiomyopathy Therapeutic Revenue
3.4 Global Dilated Cardiomyopathy Therapeutic Market Concentration Ratio
3.4.1 Global Dilated Cardiomyopathy Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Dilated Cardiomyopathy Therapeutic Revenue in 2023
3.5 Dilated Cardiomyopathy Therapeutic Key Players Head office and Area Served
3.6 Key Players Dilated Cardiomyopathy Therapeutic Product Solution and Service
3.7 Date of Enter into Dilated Cardiomyopathy Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Dilated Cardiomyopathy Therapeutic Breakdown Data by Type
4.1 Global Dilated Cardiomyopathy Therapeutic Historic Market Size by Type (2019-2024)
4.2 Global Dilated Cardiomyopathy Therapeutic Forecasted Market Size by Type (2025-2030)
5 Dilated Cardiomyopathy Therapeutic Breakdown Data by Application
5.1 Global Dilated Cardiomyopathy Therapeutic Historic Market Size by Application (2019-2024)
5.2 Global Dilated Cardiomyopathy Therapeutic Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Dilated Cardiomyopathy Therapeutic Market Size (2019-2030)
6.2 North America Dilated Cardiomyopathy Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Dilated Cardiomyopathy Therapeutic Market Size by Country (2019-2024)
6.4 North America Dilated Cardiomyopathy Therapeutic Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Dilated Cardiomyopathy Therapeutic Market Size (2019-2030)
7.2 Europe Dilated Cardiomyopathy Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Dilated Cardiomyopathy Therapeutic Market Size by Country (2019-2024)
7.4 Europe Dilated Cardiomyopathy Therapeutic Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size (2019-2030)
8.2 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Region (2019-2024)
8.4 Asia-Pacific Dilated Cardiomyopathy Therapeutic Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Dilated Cardiomyopathy Therapeutic Market Size (2019-2030)
9.2 Latin America Dilated Cardiomyopathy Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Dilated Cardiomyopathy Therapeutic Market Size by Country (2019-2024)
9.4 Latin America Dilated Cardiomyopathy Therapeutic Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size (2019-2030)
10.2 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Country (2019-2024)
10.4 Middle East & Africa Dilated Cardiomyopathy Therapeutic Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Array BioPharma, Inc.
11.1.1 Array BioPharma, Inc. Company Detail
11.1.2 Array BioPharma, Inc. Business Overview
11.1.3 Array BioPharma, Inc. Dilated Cardiomyopathy Therapeutic Introduction
11.1.4 Array BioPharma, Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2019-2024)
11.1.5 Array BioPharma, Inc. Recent Development
11.2 AstraZeneca plc.
11.2.1 AstraZeneca plc. Company Detail
11.2.2 AstraZeneca plc. Business Overview
11.2.3 AstraZeneca plc. Dilated Cardiomyopathy Therapeutic Introduction
11.2.4 AstraZeneca plc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2019-2024)
11.2.5 AstraZeneca plc. Recent Development
11.3 Celladon Corporation
11.3.1 Celladon Corporation Company Detail
11.3.2 Celladon Corporation Business Overview
11.3.3 Celladon Corporation Dilated Cardiomyopathy Therapeutic Introduction
11.3.4 Celladon Corporation Revenue in Dilated Cardiomyopathy Therapeutic Business (2019-2024)
11.3.5 Celladon Corporation Recent Development
11.4 GlaxoSmithKline plc
11.4.1 GlaxoSmithKline plc Company Detail
11.4.2 GlaxoSmithKline plc Business Overview
11.4.3 GlaxoSmithKline plc Dilated Cardiomyopathy Therapeutic Introduction
11.4.4 GlaxoSmithKline plc Revenue in Dilated Cardiomyopathy Therapeutic Business (2019-2024)
11.4.5 GlaxoSmithKline plc Recent Development
11.5 Janssen Pharmaceuticals, Inc. (J&J)
11.5.1 Janssen Pharmaceuticals, Inc. (J&J) Company Detail
11.5.2 Janssen Pharmaceuticals, Inc. (J&J) Business Overview
11.5.3 Janssen Pharmaceuticals, Inc. (J&J) Dilated Cardiomyopathy Therapeutic Introduction
11.5.4 Janssen Pharmaceuticals, Inc. (J&J) Revenue in Dilated Cardiomyopathy Therapeutic Business (2019-2024)
11.5.5 Janssen Pharmaceuticals, Inc. (J&J) Recent Development
11.6 Merck & Co., Inc.
11.6.1 Merck & Co., Inc. Company Detail
11.6.2 Merck & Co., Inc. Business Overview
11.6.3 Merck & Co., Inc. Dilated Cardiomyopathy Therapeutic Introduction
11.6.4 Merck & Co., Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2019-2024)
11.6.5 Merck & Co., Inc. Recent Development
11.7 Novartis International AG
11.7.1 Novartis International AG Company Detail
11.7.2 Novartis International AG Business Overview
11.7.3 Novartis International AG Dilated Cardiomyopathy Therapeutic Introduction
11.7.4 Novartis International AG Revenue in Dilated Cardiomyopathy Therapeutic Business (2019-2024)
11.7.5 Novartis International AG Recent Development
11.8 Pfizer, Inc.
11.8.1 Pfizer, Inc. Company Detail
11.8.2 Pfizer, Inc. Business Overview
11.8.3 Pfizer, Inc. Dilated Cardiomyopathy Therapeutic Introduction
11.8.4 Pfizer, Inc. Revenue in Dilated Cardiomyopathy Therapeutic Business (2019-2024)
11.8.5 Pfizer, Inc. Recent Development
11.9 Sanofi S.A.
11.9.1 Sanofi S.A. Company Detail
11.9.2 Sanofi S.A. Business Overview
11.9.3 Sanofi S.A. Dilated Cardiomyopathy Therapeutic Introduction
11.9.4 Sanofi S.A. Revenue in Dilated Cardiomyopathy Therapeutic Business (2019-2024)
11.9.5 Sanofi S.A. Recent Development
11.10 Teva Pharmaceutical Industries Ltd.
11.10.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.10.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.10.3 Teva Pharmaceutical Industries Ltd. Dilated Cardiomyopathy Therapeutic Introduction
11.10.4 Teva Pharmaceutical Industries Ltd. Revenue in Dilated Cardiomyopathy Therapeutic Business (2019-2024)
11.10.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.11 Vericel Corporation
11.11.1 Vericel Corporation Company Detail
11.11.2 Vericel Corporation Business Overview
11.11.3 Vericel Corporation Dilated Cardiomyopathy Therapeutic Introduction
11.11.4 Vericel Corporation Revenue in Dilated Cardiomyopathy Therapeutic Business (2019-2024)
11.11.5 Vericel Corporation Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
